What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?

Is there objective evidence demonstrating a benefit of consolidative durvalumab or prophylactic cranial irradiation in patients with stage I small cell lung cancer?

Answer from: Medical Oncologist at Academic Institution

In the ADRIATIC study, stage I or II limited-stage SCLC comprised only about 12% of patients randomized. The point estimate of HR regarding survival benefit was 0.92, with a wide confidence interval exceeding 1.0 (upper range more than 2). I do not recommend durvalumab consolidation for those with s...

Comments

Medical Oncologist at Mary Bird Perkins
What if a patient undergoes surgery and pathologic...

Medical Oncologist at Mercy Health - St. Rita's Medical Center
I would give him adjuvant chemotherapy followed by...

Medical Oncologist at University of Nebraska Medical Center
There is currently no data to use durvalumab in re...

Please select the option that best describes you:

What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?

Related Questions